ArticleFrontiers in oncology2021
Optimizing
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Synergistic Effect of Linebacker-1 With Radiation Therapy in a Mouse Lung Cancer Model.Advances in radiation oncology · 2026Article
- CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Long-Term Survival Analysis of Neoadjuvant Chemoradiotherapy Versus Adjuvant Chemoradiotherapy for Locally Advanced Low Rectal Cancer.Cancer medicine · 2025Observational
- Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment.Molecular cancer · 2025Article
- PRIMERS: Polydopamine Radioimmunotherapy with Image-Guided Monitoring and Enhanced Release System.Pharmaceutics · 2024Article
- An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: 'R-ISV-FOLactis' trial.Future oncology (London, England) · 2024Article
- Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination.Nanomaterials (Basel, Switzerland) · 2023Review
- Polydopamine Nanomaterials for Overcoming Current Challenges in Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2023Review
- Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.Oncoimmunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 4 countries.
Funding
Abstract
Effective
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.